163 related articles for article (PubMed ID: 36896214)
1. Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era.
Oertel M; Hering D; Nacke N; Kittel C; Kröger K; Kriz J; Fuchs M; Baues C; Vordermark D; Engenhart-Cabillic R; Herfarth K; Lukas P; Schmidberger H; Marnitz S; Borchmann P; Engert A; Haverkamp U; Eich HT
Adv Radiat Oncol; 2023; 8(3):101169. PubMed ID: 36896214
[TBL] [Abstract][Full Text] [Related]
2. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
Müller RP; Eich HT
Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
[TBL] [Abstract][Full Text] [Related]
3. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).
Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfart K; Lukas P; Plütschow A; Schmidberger H; Staar S; Fuchs M; Engert A; Eich HT
Strahlenther Onkol; 2017 Feb; 193(2):109-115. PubMed ID: 27596217
[TBL] [Abstract][Full Text] [Related]
4. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
[TBL] [Abstract][Full Text] [Related]
5. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
Weber DC; Peguret N; Dipasquale G; Cozzi L
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
[TBL] [Abstract][Full Text] [Related]
6. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
7. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma.
Verhappen MH; Poortmans PM; Raaijmakers E; Raemaekers JM
Radiother Oncol; 2013 Oct; 109(1):133-9. PubMed ID: 24021344
[TBL] [Abstract][Full Text] [Related]
8. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT).
Yahalom J
Eur J Haematol Suppl; 2005 Jul; (66):90-7. PubMed ID: 16007875
[TBL] [Abstract][Full Text] [Related]
9. Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial.
Oertel M; Hering D; Baues C; Kittel C; Fuchs M; Kriz J; Kröger K; Vordermark D; Herfarth K; Engenhart-Cabillic R; Lukas P; Haverkamp U; Borchmann P; Eich HT
Front Oncol; 2023; 13():1183906. PubMed ID: 37213291
[TBL] [Abstract][Full Text] [Related]
10. New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.
Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfarth K; Lukas P; Schmidberger H; Marnitz-Schulze S; Fuchs M; Engert A; Eich HT
Strahlenther Onkol; 2017 Feb; 193(2):100-108. PubMed ID: 27678010
[TBL] [Abstract][Full Text] [Related]
11. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Baues C; Goergen H; Fuchs M; Rosenbrock J; Celik E; Eich H; Kobe C; Voltin CA; Engert A; Borchmann P; Marnitz S
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):900-906. PubMed ID: 34389407
[TBL] [Abstract][Full Text] [Related]
12. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
[TBL] [Abstract][Full Text] [Related]
13. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
14. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
[TBL] [Abstract][Full Text] [Related]
15. The radiotherapy reference panel--experiences and results of the German Hodgkin Study Group (GHSG).
Eich HT; Müller RP
Eur J Haematol Suppl; 2005 Jul; (66):98-105. PubMed ID: 16007876
[TBL] [Abstract][Full Text] [Related]
16. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
18. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy.
Filippi AR; Ragona R; Fusella M; Botticella A; Fiandra C; Ricardi U
Pract Radiat Oncol; 2013; 3(3):216-222. PubMed ID: 24674367
[TBL] [Abstract][Full Text] [Related]
19. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
20. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
Hodgson DC; Koh ES; Tran TH; Heydarian M; Tsang R; Pintilie M; Xu T; Huang L; Sachs RK; Brenner DJ
Cancer; 2007 Dec; 110(11):2576-86. PubMed ID: 17941006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
